|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | ||||||||||||||||||||
| Agency securities, at fair value (including pledged securities of $80,761 and $74,149, respectively) | ||||||||||||||||||||
| Agency securities transferred to consolidated variable interest entities, at fair value (pledged securities) | ||||||||||||||||||||
| Credit risk transfer securities, at fair value (including pledged securities of $525 and $558, respectively) | ||||||||||||||||||||
| Non-Agency securities, at fair value, and other mortgage credit investments (including pledged securities of $8 and $13, respectively) | ||||||||||||||||||||
| U.S. Treasury securities, at fair value (including pledged securities of $11,295 and $13,056, respectively) | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Derivative assets, at fair value | ||||||||||||||||||||
| Receivable for investment securities sold (including pledged securities of $201 and $149, respectively) | ||||||||||||||||||||
| Receivable under reverse repurchase agreements | ||||||||||||||||||||
| Goodwill and other intangible assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Repurchase Agreements | ||||||||||||||||||||
| Debt of consolidated variable interest entities, at fair value | ||||||||||||||||||||
| Payable for investment securities purchased | ||||||||||||||||||||
| Derivative liabilities, at fair value | ||||||||||||||||||||
| Dividends payable | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders' equity: | ||||||||||||||||||||
| Preferred Stock - aggregate liquidation preference of $2,033 | ||||||||||||||||||||
| Common stock - $0.01 par value; 2,250 shares authorized, 1,164.2 and 1,107.6 shares issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
| Obligation to Return Securities Borrowed Under Reverse Repurchase Agreements at Fair Value | ||||||||||||||||||||
Loading...
